Novavax
As of the edition of 20 October 2026, Novavax runs 4 drugs, 2 of them marketed.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 2 |
| Active | 2 |
| Total | 4 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Estradiol | Ends 2032 (patent) | 6 |
| Mivalsecovatein | none listed | 0 |
A route B row is one company at one target.
Where its trials are
- Infections: 12 trials led
- Lungs and airways: 12 trials led